Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

导出原文传递

翻译打印收藏纠错

作者： Infante, Jeffrey R. ^[1] ; Hollebecque, Antoine ^[2] ; Postel-Vinay, Sophie ^[3] ; Bauer, Todd M. ^[4] ; Blackwood, Elizabeth M. ; Evangelista, Marie ; Mahrus, Sami ; Peale, Franklin V. ; Lu, Xuyang ; Sahasranaman, Srikumar ; Zhu, Rui ; Chen, Yuan ; Ding, Xiao ; Murray, Elaine R. ; Schutzman, Jennifer L. ; Lauchle, Jennifer O. ; Soria, Jean-Charles ; LoRusso, Patricia M.

作者单位： Genentech Inc, San Francisco, CA 94080 USA ^[1] Univ Paris Saclay, Gustave Roussy, DITEP, Villejuif, France ^[2] Karmanos Canc Inst, Detroit, MI USA ^[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA ^[4]

发布时间 2018-03-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2017年23卷10期

2423-2432页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除